New combo could ease anemia for kidney patients on dialysis
NCT ID NCT06115421
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a low dose of the drug Roxadustat, combined with iron, can safely and effectively treat anemia in people with kidney disease who are on dialysis. The trial involved 72 adults and compared the combination to standard treatment with erythropoietin-stimulating agents. Researchers measured changes in hemoglobin levels, iron levels, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Roxadustat (a drug that helps the body produce more red blood cells) plus iron
- What this could lead to
- If successful, this could offer a safer, lower-dose option to manage anemia in dialysis patients, potentially reducing side effects and improving quality of life.
- What could go wrong
- This is a small, completed Phase 4 trial with only 72 participants. Results may not apply to all patients, and the drug may still cause side effects or not work as well as standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANEMIA IN DIALYSIS-DEPENDENT CKD PATIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alexandria University
Alexandria, Egypt